J. Blay

Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

S. Sleijfer, F. Collin, M. van Glabbeke, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer

J. Blay, V. Grégoire, B. Fervers, 2021, ESMO open.

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.

A. Tolcher, J. Soria, V. Diéras, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.

J. Blay, S. Boyault, S. Lantuejoul, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Policy strategies for capacity building and scale up of the workforce for comprehensive cancer care: a systematic review

J. Blay, G. Curigliano, D. Moreira, 2024, ESMO open.

Joint adolescent–adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform—ACCELERATE

K. Norga, L. Marshall, P. Blanc, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations.

J. Blay, G. Ferretti, J. Mazières, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.